NovelMed is a cutting edge clinical-stage biotech
We are a privately-held biotechnology company developing novel therapies for orphan and non-orphan diseases with a specific focus on blocking certain parts of the immune system involved in the disease process. With our unique portfolio of neutralizing monoclonal antibodies, NovelMed is targeting chronic diseases with large market potential and unmet medical need.
We are continuously inventing and developing novel complement-based therapies for unmet needs. Over the last decade, we have generated pre-clinical data and accumulated significant intellectual property to cover the discovery and development of our humanized antibody platform. As a result, we have created an exciting pipeline of therapeutic candidates. Our portfolio of therapeutic antibodies target the chronic rare diseases of our time, and they have demonstrated a better safety and efficacy profile than currently marketed drugs. NovelMed utilizes an innovative R&D strategy, which enables us to block certain parts of the immune system involved with the development and progression of rare diseases. Our portfolio of antibodies are filtered through a unique research pattern to identify best-fit candidates for further development and to treat specific clinical indications.
We have achieved remarkable clinical success in advancing multiple antibodies that have a superior mechanism of action compared to those currently under development at other pharmaceutical companies. Our preclinical and clinical studies provide compelling evidence that these antibodies are likely to have a higher level of selectivity and efficacy than competing antibody therapies. Moreover, our antibodies have the potential to be safer due to selectivity for the alternative complement pathway.
We have generated significant Phase I clinical data and plan to start Phase II trials for the following orphan and non-orphan indications:
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Atypical Hemolytic Uremic Syndrome (aHUS)
C3 Glomerulopathy (C3G)
Idiopathic Membranous Nephropathy (iMN)
IgA Nephropothy (IgAN)
Amyotrophic Lateral Sclerosis (ALS)
Generalized Myasthenia Gravis (gMG)
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Geographic Atrophy (GA)
Wet Age Related Macular Degeneration (Wet AMD)
Rheumatoid Arthritis (RA)
Cardiopulmonary Bypass (CPB)
Dr. Bansal has over 20 years of experience in the Biotech industry. Prior to founding NovelMed, Dr. Bansal gained significant experience at Gliatech, a pharma company in Cleveland Ohio. Dr. Bansal has also worked with Janssen and Amgen. As NovelMed's Founder and Chief Scientific Officer, Dr. Bansal leads all pre-clinical and clinical programs. She has over 15 years of experience in complement-mediated inflammatory disorders and humanized monoclonal antibodies. She has obtained several federal and non-federal funding to support the research and development programs at NovelMed. She had developed a strong intellectual property portfolio of anti-complement monoclonal antibodies. Dr. Bansal has guided the development of lead drug candidates from invention to clinic.
The foundation of all our efforts as it is important for patients.
Maintain high ethical standards for our research, services, and communications.
Provide value for patients, healthcare providers, employees, and investors.
Invite best-in-class scientists, inventors and committed people. Provide an environment that fosters honesty, & respect,
To have the First-in-class diagnostics and Novel drugs to treat rare diseases
Science that redefines what is humanly possible to create as a First-in-class medicines.for rare diseases